Table 2 Adverse events during neoadjuvant chemotherapy and immunotherapy and definitive chemoradiotherapy.
Grade of adverse event, no. (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|---|---|
Immune-related adverse events during nCIT | |||||
Rash | 1 (1.7) | 0 | 0 | 0 | 0 |
Thyroid function abnormalities | 5 (8.9) | 0 | 0 | 0 | 0 |
ALT/AST abnormalities | 10 (17.9) | 0 | 0 | 0 | 0 |
Renal function abnormalities | 4 (7.1) | 0 | 0 | 0 | 0 |
Cardiac arrhythmia | 6 (10.7) | 0 | 0 | 0 | 0 |
Fatigue | 10 (17.9) | 0 | 0 | 0 | 0 |
Decreased appetite | 14 (25) | 0 | 0 | 0 | 0 |
Myocarditis | 0 | 0 | 2 (3.6) | 0 | 0 |
Enterocolitis | 0 | 0 | 1 (1.7) | 0 | 0 |
Pneumonitis | 0 | 1 (1.7) | 0 | 0 | 0 |
Adverse events during definitive chemoradiotherapy/radiotherapy | |||||
Leukopenia | 12 (20.7) | 24 (41.4) | 11 (19.0) | 0 | 0 |
Thrombocytopenia | 7 (12.1) | 16 (37.6) | 6 (10.3) | 1 (1.7) | |
Anemia | 25 (43.1) | 22 (37.9) | 7 (12.1) | 1 (1.7) | |
Radiation esophagitis | 21 (37.5) | 16 (28.6) | 8 (14.3) | 4 (7.2) | 6 (10.7) |
Radiation pneumonitis | 14 (25.0) | 14 (25.0) | 3 (5.4) | 2 (3.6) | 2 (3.6) |
